HC Wainwright Raises Mirum Pharmaceuticals Price Target to $200
HC Wainwright & Co. raised its price target on Mirum Pharmaceuticals to $200 per share from $195 and maintained its Buy rating.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.